Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 April 2006Website:
http://www.metagenomi.coNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 14 min agoDividend
Analysts recommendations
Institutional Ownership
MGX Latest News
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113059&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113043&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Metagenomi between February 9, 2024 and September 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 21, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) and reminds investors of the November 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=112942&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK CITY, NY / ACCESSWIRE / November 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9, 2024, and May 1, 2024, inclusive (the "Class Period").
NEW YORK , Nov. 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=112908&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=112840&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / November 19, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=112681&wire=1 or contact Joseph E. Levi, Esq.
What type of business is Metagenomi Common Stock?
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
What sector is Metagenomi Common Stock in?
Metagenomi Common Stock is in the Healthcare sector
What industry is Metagenomi Common Stock in?
Metagenomi Common Stock is in the Biotechnology industry
What country is Metagenomi Common Stock from?
Metagenomi Common Stock is headquartered in United States
When did Metagenomi Common Stock go public?
Metagenomi Common Stock initial public offering (IPO) was on 06 April 2006
What is Metagenomi Common Stock website?
https://www.metagenomi.co
Is Metagenomi Common Stock in the S&P 500?
No, Metagenomi Common Stock is not included in the S&P 500 index
Is Metagenomi Common Stock in the NASDAQ 100?
No, Metagenomi Common Stock is not included in the NASDAQ 100 index
Is Metagenomi Common Stock in the Dow Jones?
No, Metagenomi Common Stock is not included in the Dow Jones index
When was Metagenomi Common Stock the previous earnings report?
No data
When does Metagenomi Common Stock earnings report?
The next expected earnings date for Metagenomi Common Stock is 28 February 2025